Duchenne Muscular Dystrophy (DMD) Market Size Expected to Hit USD 2.1 billion by 2031, Driven by Robust 4.7% CAGR: AMR

Allied Market Research has published a study report with the title Duchenne Muscular Dystrophy (DMD) Market Size was Valued at USD 1.3 billion in 2021 and is Projected to Garner USD 2.1 billion by 2031, registering a CAGR of 4.7% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

𝐂𝐨𝐯𝐢𝐝-𝟏𝟗 𝐒𝐜𝐞𝐧𝐚𝐫𝐢𝐨

• The outbreak of the Covid-19 pandemic had a negative impact on the global Duchenne muscular dystrophy market, owing to implementation of the global lockdown which led to temporary closure of many clinics, especially in the initial period.
• However, throughout the pandemic, despite the recommendations to maintain social distance, many individuals treated their illnesses via self-medication or other unconventional methods owing to their concern of contracting COVID during the lockdown.

𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐟𝐚𝐜𝐭𝐨𝐫𝐬 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐃𝐮𝐜𝐡𝐞𝐧𝐧𝐞 𝐌𝐮𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐲𝐬𝐭𝐫𝐨𝐩𝐡𝐲 𝐌𝐚𝐫𝐤𝐞𝐭?

Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healthcare services drive the growth of the global Duchenne muscular dystrophy market. However, inflated cost of treatments for Duchenne muscular dystrophy restricts the market growth. On the other hand, increase in government spending on the pharmaceutical and biotechnology sectors in developing countries, the development of healthcare infrastructure, and rise in demand for innovative treatments for Duchenne muscular dystrophy present new opportunities in the coming years.

𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐇𝐞𝐫𝐞:
https://www.alliedmarketresearch.com/request-sample/16015

𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐎𝐟 𝐃𝐮𝐜𝐡𝐞𝐧𝐧𝐞 𝐌𝐮𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐲𝐬𝐭𝐫𝐨𝐩𝐡𝐲 (𝐃𝐌𝐃)

• F Hoffmann-La Roche AG
• FibroGen, Inc
• GlaxoSmithKline plc
• Italfarmaco S.p.A.
• Nippon Shinyaku Co., Ltd
• Pfizer Inc.
• PTC Therapeutics
• Santhera Pharmaceuticals Inc
• Sarepta therapeutics
• Wave life sciences ltd.
• ABBOTT LABORATORIES

𝐃𝐮𝐜𝐡𝐞𝐧𝐧𝐞 𝐌𝐮𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐲𝐬𝐭𝐫𝐨𝐩𝐡𝐲 (𝐃𝐌𝐃) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: -

Based on therapeutic area, the molecular-based therapies segment held the highest market share in 2021, accounting for around three-fifths of the global Duchenne muscular dystrophy market, and is estimated to maintain its leadership status throughout the forecast period. In addition, the same segment is projected to manifest the highest CAGR of 5.0% from 2022 to 2031, owing to R & D activities for exon skipping drugs, strong product pipeline and significant product launch by key players. The report also discusses steroid therapy segment.

Based on distribution channel, the hospital pharmacies segment accounted for the largest share in 2021, contributing to more than three-fifths of the global Duchenne muscular dystrophy market, and is projected to maintain its lead position during the forecast period. This is owing to significant rise in the number of diagnosis through hospitals. However, the drug store & retail pharmacies segment is expected to portray the largest CAGR of 5.4% from 2022 to 2031, owing to the rise in the approval of drugs and their availability in drug store & retail pharmacies.

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than half of the global Duchenne muscular dystrophy market, and is likely to dominate the market during the forecast period. This is owing to technological advancements in Duchenne muscular dystrophy treatment and presence of key players & robust hospital infrastructure in the region.

However, the Asia-Pacific region is expected to witness the fastest CAGR of 5.9% from 2022 to 2031. This is owing to rise in cases of Duchenne muscular dystrophy, approval of drugs, development of healthcare infrastructure, and increase in investments projects in the region.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/purchase-enquiry/16015

Our Market Research Solution Provides You Answer to Below Mentioned Question:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.